{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:47:31Z","timestamp":1782179251898,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300868 and 82473503"],"award-info":[{"award-number":["82300868 and 82473503"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16101-3","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:25:18Z","timestamp":1777598718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A meta-analysis of dizziness as an adverse reaction in novel endocrine therapy for advanced prostate cancer"],"prefix":"10.1186","volume":"26","author":[{"given":"Wenbin","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Quan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"3","key":"16101_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"10159","key":"16101_CR2","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","volume":"392","author":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators","year":"2018","unstructured":"GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789\u2013858. https:\/\/doi.org\/10.1016\/S0140-6736(18)32279-7.","journal-title":"Lancet"},{"issue":"10159","key":"16101_CR3","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016-40 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(18)31694-5.","journal-title":"Lancet"},{"issue":"10305","key":"16101_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S0140-6736(21)00950-8","volume":"398","author":"S Sandhu","year":"2021","unstructured":"Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet. 2021;398(10305):1075\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(21)00950-8.","journal-title":"Lancet"},{"key":"16101_CR5","unstructured":"National Comprehensive Cancer Network. Prostate cancer. Accessed Apr 17 2024. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/"},{"issue":"3","key":"16101_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1210\/endrev\/bnab002","volume":"42","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354\u201373. https:\/\/doi.org\/10.1210\/endrev\/bnab002.","journal-title":"Endocr Rev"},{"issue":"1","key":"16101_CR7","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-022-01042-7","volume":"7","author":"Y He","year":"2022","unstructured":"He Y, Xu W, Xiao YT, Huang H, Gu D, Ren S. Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. Signal Transduct Target Ther. 2022;7(1):198. https:\/\/doi.org\/10.1038\/s41392-022-01042-7.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"16101_CR8","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/ajhp\/zxac105","volume":"79","author":"C Chung","year":"2022","unstructured":"Chung C, Abboud K. Targeting the androgen receptor signaling pathway in advanced prostate cancer. Am J Health Syst Pharm. 2022;79(15):1224\u201335. https:\/\/doi.org\/10.1093\/ajhp\/zxac105.","journal-title":"Am J Health Syst Pharm"},{"issue":"10323","key":"16101_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","volume":"399","author":"G Attard","year":"2022","unstructured":"Attard G, Murphy L, Clarke NW, et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet. 2022;399(10323):447\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(21)02437-5.","journal-title":"Lancet"},{"issue":"11","key":"16101_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, castration-resistant prostate cancer and survival with Darolutamide. N Engl J Med. 2020;383(11):1040\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2001342.","journal-title":"N Engl J Med"},{"issue":"6","key":"16101_CR11","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1097\/MOU.0000000000001341","volume":"35","author":"R Iaxx","year":"2025","unstructured":"Iaxx R, Teyssonneau D, Fallaha C, Grouthier V, Roubaud G. Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancer. Curr Opin Urol. 2025;35(6):696\u2013706. https:\/\/doi.org\/10.1097\/MOU.0000000000001341.","journal-title":"Curr Opin Urol"},{"issue":"11","key":"16101_CR12","doi-asserted-by":"publisher","first-page":"103736","DOI":"10.1016\/j.esmoop.2024.103736","volume":"9","author":"H Bolek","year":"2024","unstructured":"Bolek H, Yazgan SC, Yeked\u00fcz E, et al. Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer. ESMO Open. 2024;9(11):103736. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103736.","journal-title":"ESMO Open"},{"issue":"3","key":"16101_CR13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1001\/jamaoto.2023.4554","volume":"150","author":"ME Lin","year":"2024","unstructured":"Lin ME, Gallagher TJ, Straughan A, Marmor S, Adams ME, Choi JS. Association of symptomatic dizziness with all-cause and cause-specific mortality. JAMA Otolaryngol Head Neck Surg. 2024;150(3):257\u201364. https:\/\/doi.org\/10.1001\/jamaoto.2023.4554.","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"16101_CR14","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1002\/lary.25902","volume":"126","author":"CE Corrales","year":"2016","unstructured":"Corrales CE, Bhattacharyya N. Dizziness and death: an imbalance in mortality. Laryngoscope. 2016;126(9):2134\u20136. https:\/\/doi.org\/10.1002\/lary.25902.","journal-title":"Laryngoscope"},{"key":"16101_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jocn.2019.07.071","volume":"69","author":"B Cacho-D\u00edaz","year":"2019","unstructured":"Cacho-D\u00edaz B, Salmer\u00f3n-Moreno K, Mendoza-Olivas LG, Reynoso-Nover\u00f3n N, G\u00f3mez-Amador JL. Vertigo in patients with cancer: red flag symptoms. J Clin Neurosci. 2019;69:175\u20138. https:\/\/doi.org\/10.1016\/j.jocn.2019.07.071.","journal-title":"J Clin Neurosci"},{"key":"16101_CR16","doi-asserted-by":"publisher","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","volume":"88","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906. https:\/\/doi.org\/10.1016\/j.ijsu.2021.105906.","journal-title":"Int J Surg"},{"key":"16101_CR17","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","volume":"358","author":"BJ Shea","year":"2017","unstructured":"Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008. https:\/\/doi.org\/10.1136\/bmj.j4008.","journal-title":"BMJ"},{"key":"16101_CR18","unstructured":"v5 C. US Department of Health and Human Services NIH, National Cancer Institute. 2017. Available from: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/trial-development"},{"key":"16101_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"issue":"6","key":"16101_CR20","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1007\/s12325-022-02140-2","volume":"39","author":"YS Pu","year":"2022","unstructured":"Pu YS, Ahn H, Han W, et al. Enzalutamide in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: an Asian multiregional, randomized study. Adv Ther. 2022;39(6):2641\u201356. https:\/\/doi.org\/10.1007\/s12325-022-02140-2.","journal-title":"Adv Ther"},{"issue":"18","key":"16101_CR21","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","volume":"34","author":"DF Penson","year":"2016","unstructured":"Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016;34(18):2098\u2013106. https:\/\/doi.org\/10.1200\/JCO.2015.64.9285.","journal-title":"J Clin Oncol"},{"issue":"3","key":"16101_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.5551\/jat.31047","volume":"23","author":"S Yoshida","year":"2016","unstructured":"Yoshida S, Ikeda Y, Aihara K. Roles of the androgen--androgen receptor system in vascular angiogenesis. J Atheroscler Thromb. 2016;23(3):257\u201365. https:\/\/doi.org\/10.5551\/jat.31047.","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"16101_CR23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/s41391-024-00886-0","volume":"28","author":"A Matsukawa","year":"2025","unstructured":"Matsukawa A, Yanagisawa T, Parizi MK, et al. Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. Prostate Cancer Prostatic Dis. 2025;28(2):298\u2013308. https:\/\/doi.org\/10.1038\/s41391-024-00886-0.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"16101_CR24","doi-asserted-by":"publisher","first-page":"110030","DOI":"10.1016\/j.cbi.2022.110030","volume":"363","author":"M Kenda","year":"2022","unstructured":"Kenda M, Zore T, SollnerDolenc M. Effects of central nervous system drugs on androgen, estrogen \u03b1, glucocorticoid, and thyroid receptors. Chem Biol Interact. 2022;363:110030. https:\/\/doi.org\/10.1016\/j.cbi.2022.110030.","journal-title":"Chem Biol Interact"},{"key":"16101_CR25","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.mce.2017.09.001","volume":"465","author":"JJ Morford","year":"2018","unstructured":"Morford JJ, Wu S, Mauvais-Jarvis F. The impact of androgen actions in neurons on metabolic health and disease. Mol Cell Endocrinol. 2018;465:92\u2013102. https:\/\/doi.org\/10.1016\/j.mce.2017.09.001.","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"16101_CR26","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/17425255.2025.2478167","volume":"21","author":"C Ib\u00e1\u00f1ez","year":"2025","unstructured":"Ib\u00e1\u00f1ez C, Tour\u00eds-Lores M, Montesa \u00c1, et al. Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage. Expert Opin Drug Metab Toxicol. 2025;21(6):625\u201336. https:\/\/doi.org\/10.1080\/17425255.2025.2478167.","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"16101_CR27","doi-asserted-by":"publisher","first-page":"1570661","DOI":"10.3389\/fphar.2025.1570661","volume":"16","author":"J Wang","year":"2025","unstructured":"Wang J, You J, Huang W, et al. The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis. Front Pharmacol. 2025;16:1570661. https:\/\/doi.org\/10.3389\/fphar.2025.1570661. Published 2025 Mar 27.","journal-title":"Front Pharmacol"},{"issue":"8","key":"16101_CR28","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1093\/jnci\/djac081","volume":"114","author":"LY Lai","year":"2022","unstructured":"Lai LY, Oerline MK, Caram MEV, et al. Risk of metabolic and cardiovascular adverse events with Abiraterone or Enzalutamide among men with advanced prostate cancer. J Natl Cancer Inst. 2022;114(8):1127\u201334. https:\/\/doi.org\/10.1093\/jnci\/djac081.","journal-title":"J Natl Cancer Inst"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16101-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16101-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T01:03:13Z","timestamp":1782176593000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16101-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16101"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16101-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"765"}}